The FDA has approved a new drug called Lenvima, also known as lenvatinib, for adults with a certain kind of thyroid cancer. This cancer is called differentiated thyroid cancer. It has come back in the same area or spread to other parts of the body. It has also stopped responding to radioactive iodine, a common treatment. These patients often have few good treatment choices left.
Lenvima is a pill taken once a day. The usual dose is 24 mg. Patients keep taking it until the cancer gets worse or side effects become too much. The drug works by blocking certain proteins that help cancer cells grow. The label includes ways to lower the dose if needed, and special guidance for people with kidney or liver problems.
This approval offers doctors a new systemic therapy, meaning a drug that travels through the body, for patients with this progressive cancer. It is an important step for a group with limited options.
One honest note: the approval announcement does not include data from clinical trials. So we cannot say how well it works compared to other treatments or whether it helps people live longer. If you or someone you love has this type of thyroid cancer, talk with your doctor. They can help you understand if this drug is right for you.
